220 related articles for article (PubMed ID: 30677858)
21. Severe vemurafenib-induced photosensitivity in a 6-year-old boy.
Jew OS; Provini LE; Treat JR
Pediatr Dermatol; 2019 Jan; 36(1):e62-e63. PubMed ID: 30474875
[TBL] [Abstract][Full Text] [Related]
22. A Case of Perforating Folliculitis Induced by Vemurafenib.
Shiraishi K; Masunaga T; Tohyama M; Sayama K
Acta Derm Venereol; 2019 Feb; 99(2):230-231. PubMed ID: 30281138
[No Abstract] [Full Text] [Related]
23. Acne inversa-like lesions and acneiform eruption associated with vemurafenib and cobimetinib used for advanced melanoma.
Bostan E; Akdogan N
J Cosmet Dermatol; 2021 Jun; 20(6):1944-1945. PubMed ID: 33012095
[No Abstract] [Full Text] [Related]
24. Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
Rhee do Y; Won KH; Lee YJ; Won CH; Chang SE; Lee MW
J Dermatolog Treat; 2016 Oct; 27(5):448-9. PubMed ID: 27092864
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous adverse events during vemurafenib therapy.
Chandrakumar SF; Yeung J
J Cutan Med Surg; 2014; 18(4):223-8. PubMed ID: 25008438
[TBL] [Abstract][Full Text] [Related]
26. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
[TBL] [Abstract][Full Text] [Related]
28. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Shin JU; Park JH; Cho BC; Lee JH
Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
[TBL] [Abstract][Full Text] [Related]
29. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients.
Katzer K; Tietze J; Klein E; Heinemann V; Ruzicka T; Wollenberg A
Eur J Dermatol; 2010; 20(1):82-4. PubMed ID: 19797039
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
31. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.
Boyd KP; Vincent B; Andea A; Conry RM; Hughey LC
J Am Acad Dermatol; 2012 Dec; 67(6):1375-9. PubMed ID: 22940405
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V) (600) mutations.
Yamazaki N; Kiyohara Y; Sugaya N; Uhara H
J Dermatol; 2015 Jul; 42(7):661-6. PubMed ID: 25884515
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
34. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
35. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.
Regnier-Rosencher E; Lazareth H; Gressier L; Avril MF; Thervet E; Dupin N
Br J Dermatol; 2013 Oct; 169(4):934-8. PubMed ID: 23909652
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of a child with MEK inhibitor-induced acneiform eruption with low-dose isotretinoin.
Gupta R; Craddock MF
Pediatr Dermatol; 2022 Jul; 39(4):646-647. PubMed ID: 35896172
[TBL] [Abstract][Full Text] [Related]
37. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF
Blank CU; Larkin J; Arance AM; Hauschild A; Queirolo P; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Garbe C; Chiarion Sileni V; Mandalà M; Gogas H; Espinosa E; Hospers GAP; Miller WH; Robson S; Makrutzki M; Antic V; Brown MP
Eur J Cancer; 2017 Jul; 79():176-184. PubMed ID: 28501764
[TBL] [Abstract][Full Text] [Related]
38. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy.
Gutzmer R; Werfel T; Mao R; Kapp A; Elsner J
Br J Dermatol; 2005 Oct; 153(4):849-51. PubMed ID: 16181478
[No Abstract] [Full Text] [Related]
40. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.
Uribe P; Anforth RM; Kefford RF; Fernandez-Peñas P
Melanoma Res; 2014 Oct; 24(5):501-3. PubMed ID: 24922191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]